Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 29, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Pancreatitis, ChronicPancreatitis, AcuteDiabetes Mellitus
Interventions
DRUG

Pioglitazone (PIO)

Subjects will take 30 mg tablet, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 45 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c \>7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food till 24 weeks.

DRUG

Empagliflozin (EMPA)

Subjects will start with 10 mg dose, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 25 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c \>7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food.

Trial Locations (2)

15219

NOT_YET_RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

55905

RECRUITING

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

University of Pittsburgh Medical Center

OTHER

lead

Mayo Clinic

OTHER

NCT06729996 - Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus | Biotech Hunter | Biotech Hunter